جستجوی استاد راهنمای دانشگاهی

Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.

• Mass Spectrometry
• Proteomics
• Systems Biology
• +۶ مورد دیگر

Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788

• Molecular Immunology
• Cell Signaling
• Signal Transduction Pathways
• +۴ مورد دیگر

Dr. Angelika Rambold is a Group Leader at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany, heading the Laboratory for Metabolic Organelle Networks in Immunology within the Department of Developmental Immunology. Previously affiliated with the University of Münster's Center for Molecular Biology of Inflammation (ZMBE) and Institute of Medical Biochemistry until January 2025, she investigates how intracellular organelle networks regulate immune cell function during inflammation, infection, and metabolic stress. Her research centers on dynamic interactions between mitochondria, lysosomes, lipid droplets, and autophagosomes during cellular adaptation to nutrient deprivation and pathogen challenge. Key interests include organelle communication mechanisms in immune cell activation, metabolic reprogramming in T cells and macrophages, and how defects in organelle networks drive primary immunodeficiencies like Chediak-Higashi syndrome. She employs advanced live-cell microscopy, super-resolution imaging, metabolomics, and single-cell transcriptomics to dissect these processes in primary immune cells and human disease models. Analysis of her publication record reveals consistent focus on mitochondrial dynamics as a central regulator of immune cell metabolism and fate determination. Landmark studies demonstrate TFEB-mediated itaconate synthesis for bacterial control in macrophages and coordinated organelle network responses during starvation, establishing critical links between organelle communication, immunometabolism, and disease pathogenesis across multiple immune cell types. Dr. Rambold serves as a supervisor in the Cells in Motion International Max Planck Research School (CiM-IMPRS) Graduate Programme, mentoring PhD students in interdisciplinary research. Her laboratory maintains active collaboration with the Center for Chronic Immunodeficiency (CCI) at the University of Freiburg to translate basic findings on organelle-mediated immune defects into clinical insights for patient-oriented research.

• Immunology
• Cell Biology
• Metabolism
• +۳ مورد دیگر

Stefan Kluge is a Professor at the Department of Intensive Care within the University Medical Center Hamburg-Eppendorf . With over 150 publications in 2025-2024 alone, his work focuses on critical care medicine, sepsis, ARDS, and cardiogenic shock. His recent research explores ARDS impact on liver cirrhosis outcomes Hyperoxia effects in traumatic brain injury Biomarkers for cardiogenic shock prognosis Novel retrograde limb perfusion techniques during ECPR Dual-energy CT for body composition analysis He contributes extensively to German national guidelines for nosocomial pneumonia and participates in multi-center critical care trials. Stefan Kluge's collaborations span neuro-intensive care , cardiovascular research , and infection/immunity domains. His work integrates machine learning applications and medical informatics to improve ICU decision-making.

• Intensive Care Medicine
• Critical Care
• Sepsis
• +۹ مورد دیگر

Prof. Dr. med. Franz Lennard Ricklefs is a Senior Physician and Head of the Working Group at the Department of Neurosurgery, University of Hamburg Faculty of Medicine. He is a Medical Specialist in Neurosurgery with cross-disciplinary expertise in neuro-oncology, molecular pathology, and extracellular vesicle research. Affiliations: University Medical Center Hamburg-Eppendorf (UKE), European Liquid Biopsy Society (ELBS), International Consortium on Meningiomas (ICOM) Research Interests: His work focuses on neurosurgical oncology, particularly glioblastoma and meningioma pathobiology. He investigates DNA methylation patterns, extracellular vesicle biomarkers, and liquid biopsy implementation in clinical neuro-oncology. Additional interests include surgical outcomes for epilepsy and aneurysm management. Article Trends: Over the last decade, Dr. Ricklefs has published extensively on: Extracellular vesicle applications as liquid biopsy markers DNA methylation subclasses for glioblastoma and meningioma Multicenter surgical outcome benchmarking Immune evasion mechanisms in neuro-oncology Technological innovations in neurosurgical visualization Molecular characterization of rare CNS tumors Professional Contributions: He co-authored the MISEV2023 guidelines for extracellular vesicle studies and participates in international consensus reviews for meningioma classification. His collaborations span institutions across Europe and North America.

• Neurosurgery
• Neuro-oncology
• Molecular Neurobiology
• +۵ مورد دیگر

Prof. Dr. Marc Schneider holds a professorship in Biopharmaceutics and Pharmaceutical Technology at Saarland University's College of Pharmacy . His research focuses on colloidal drug delivery systems, particularly nanostructured and non-spherical particle engineering for overcoming biological barriers in pulmonary and transdermal applications. He leads an internationally recognized lab in Saarbrücken, collaborating with Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and trinational institutions. Research Highlights: Development of inhalable nano/microparticle systems Surface modification of gelatin nanoparticles Characterization of mucus-penetrating particles 3D printing for microneedle fabrication Atomic Force Microscopy (AFM) for nanoparticle analysis Selected Scientific Awards: European Journal of Pharmaceutics and Biopharmaceutics Best Paper Award (2018) for mucus-penetrating nanoparticles Recognized in 'Ausgezeichnete Orte im Land der Ideen' competition (2018) for 'Nano-Mais' drug delivery system Collaborative Networks: Co-editor for Advanced Drug Delivery Reviews special issue on biological barriers Key participant in trinational Master's program in Biomedicine with Strasbourg, Mainz, and Luxembourg Active in Controlled Release Society (CRS) conferences and local chapters

• Colloidal drug delivery systems
• Nanoparticle and microparticle engineering
• Nanotechnology in pharmacy
• +۳ مورد دیگر

Privatdozent Dr. Andreas Faust is a leading researcher at the European Institute for Molecular Imaging (EIMI) at the University of Münster, where he heads the Chemical Targeting Lab. His work focuses on developing innovative imaging agents for medical diagnostics, particularly in radiopharmaceutical chemistry and molecular imaging. He maintains strong affiliations with the Department of Nuclear Medicine at the University Hospital Münster and participates in the "Cells in Motion" excellence cluster, contributing to cutting-edge research at the intersection of chemistry, medicine, and imaging technology. Dr. Faust completed his chemistry studies at the University of Münster, earning his Diploma in 1999, followed by his doctoral degree (Dr. rer. nat.) in 2003 with research on artificial caffeine receptors. His academic journey continued with positions at the Department of Organic Chemistry and the Department of Nuclear Medicine before becoming head of the chemistry group at EIMI in 2011. Dr. Faust's research centers on organic and medicinal chemistry with specialization in radiopharmaceutical chemistry . His team develops novel tracers for diagnostic molecular imaging using positron emission tomography (PET), single-photon emission computed tomography (SPECT), optical imaging, and photoacoustic imaging. A significant portion of his work focuses on creating specific ligands for the alarmins S100A8/S100A9 and bacteria-specific tracers based on complex carbohydrates or siderophores. His research has important applications in inflammation imaging, infection diagnostics, and cancer theranostics, with emphasis on improving metabolic stability and target specificity of imaging agents. His publication record demonstrates consistent contributions to molecular imaging, with recent work emphasizing bacteria-specific PET tracers, inflammation imaging targeting S100 proteins, and novel optical imaging probes. The research shows a clear trajectory toward developing clinically applicable imaging agents with improved specificity and metabolic stability, particularly in the areas of infection diagnostics and inflammation monitoring. 2017: Best Poster Award at Symposium "Molecular Imaging Agents in Medicine," Groningen 2009: Young Investigator Award at Deutscher Röntgenkongress, Berlin 2005: Best Scientific Poster Award at 4th Annual Meeting of the Society of Molecular Imaging, Köln Dr. Faust leads multiple significant research projects, including as Coordinator of a project on immune cell distribution imaging (2019-2024) and as Principal Investigator for CRC-project A03 "Targeting of S100A8/A9 for imaging of inflammatory disorders" and research on vascular graft infections (both 2021-2024). His Chemical Targeting Lab comprises a multidisciplinary team working at the intersection of chemistry, microbiology, and medical imaging, securing substantial funding from the Innovative Medicines Initiative and DFG Collaborative Research Centre. The Chemical Targeting Lab maintains state-of-the-art facilities for chemical synthesis, radiochemistry, and biological testing. The lab collaborates extensively with microbiologists, clinicians, and imaging specialists to translate basic research into clinical applications. Current research directions include optimizing bacterial imaging probes for clinical diagnostics and developing new inflammation-specific tracers for early disease detection, with particular focus on S100A9-targeted imaging and siderophore-based bacterial detection systems.

• organic chemistry
• medicinal chemistry
• radiopharmaceutical chemistry
• +۷ مورد دیگر

Brenda Schulman is a Professor and Director of the Molecular Machines and Signaling Pathways department at the Max Planck Institute of Biochemistry in Martinsried, Germany. She also holds an honorary professorship at the Technical University of Munich's Department of Chemistry and serves as Adjunct Faculty at St. Jude Children's Research Hospital in Memphis, TN, USA. Her research focuses on understanding how ubiquitin and ubiquitin-like proteins regulate cellular processes through protein modification. Dr. Schulman's research interests center on structural biology of the ubiquitin-proteasome system and ubiquitin-like proteins. Her work has shown that hundreds of dynamic multiprotein complexes are transiently converted into different conformations by specialized regulatory factors that control ubiquitin and ubiquitin-like proteins, thereby monitoring virtually all processes in cell biology. She combines biochemical reconstitution, structural analysis, enzymology, protein design, cell biology, and genetics to understand how these molecular machines function. Her research has significant implications for understanding diseases such as cancer, neurodegenerative disorders, and viral infections where defects in ubiquitin pathways are implicated. Her extensive publication record demonstrates expertise in ubiquitin signaling, protein degradation mechanisms, structural biology of E3 ligases, and molecular machines. Her work spans from fundamental mechanisms of ubiquitin chain formation to therapeutic applications in targeted protein degradation. Among her numerous scientific accolades are the Feldberg Prize for Anglo-German Scientific Exchange (2025), ERC Advanced Grant (2023), Louis-Jeantet Prize for Medicine (2023), Gottfried Wilhelm Leibniz Prize (2019), and election to the National Academy of Sciences (2014). She has also received the Dorothy Crowfoot Hodgkin Award from The Protein Society and has been an Investigator of the Howard Hughes Medical Institute. Dr. Schulman leads an active research group that has produced numerous high-impact publications in top journals including Nature, Cell, and Nature Structural & Molecular Biology. Her team has made significant contributions to understanding the structural mechanisms of ubiquitin transfer, E3 ligase specificity, and the role of ubiquitin in cellular quality control pathways. Current research in her lab focuses on deciphering the ubiquitin code and developing novel approaches for targeted protein degradation.

• Structural biology
• Ubiquitin-proteasome system
• Ubiquitin-like proteins
• +۵ مورد دیگر

PD Dr. Michael Veit is an Associate Professor (Privatdozent) at the Institute of Virology, School of Veterinary Medicine, Freie Universität Berlin , where he heads the independent Research Group Veit – Cell Biology of Viral Infections . He is a faculty member of the Center for Infection Medicine and participates in the Berlin Equine Virus Lab (BEVL). Education & Training Doctorate (Dr. rer. nat.) in Virology/Biochemistry – exact institution not stated in text. Post-doctoral qualification (Privatdozent) awarded by Freie Universität Berlin. Research Focus Veit’s laboratory investigates the molecular and cellular biology of enveloped RNA viruses , with emphasis on virus–host membrane interactions and post-translational lipid modifications (S-acylation/palmitoylation). His group combines reverse genetics, live-cell imaging, mass spectrometry and structural approaches to dissect how viral glycoproteins are modified, trafficked and assembled into infectious particles. Model pathogens include influenza A, B, C and D viruses, coronaviruses (SARS-CoV-2, MERS-like CoVs, PHEV, PDCoV), arteriviruses (PRRSV, EAV), alphaviruses (Getah, CHIKV-like), and other emerging zoonotic agents. Publication Trends From 2020 to 2025 Veit has published >30 high-impact articles that cluster around four major themes: (i) coronavirus surveillance and zoonotic risk assessment , (ii) mechanistic dissection of protein acylation in influenza and arteriviruses , (iii) structure-function analysis of viral entry receptors (ACE2, LDLR), and (iv) development of reverse-genetic tools and reporter viruses for antiviral screening. Grants & Collaborative Networks Ongoing third-party funded projects coordinated by Veit are not explicitly listed in the text, but the continuous publication output and mention of “Current Collaborations” imply active grant support. He collaborates closely with other FU Berlin groups (Osterrieder, Kaufer, Azab) and international partners on coronavirus and influenza consortia. Laboratory & Teams The Research Group Veit comprises post-docs, PhD students and technicians working in BSL-2 and BSL-3 facilities at the Institute of Virology. Core platforms include confocal & FLIM microscopy, quantitative proteomics, and reverse-genetics suites for segmented RNA viruses.

• Virology
• Viral Cell Biology
• Virus–Host Membrane Interactions
• +۵ مورد دیگر

Professor Wolfgang Fritzsche serves as Head of the Nanobiophotonics Department at the Leibniz Institute of Photonic Technology (Leibniz-IPHT) in Jena, Germany, where he leads cutting-edge research at the intersection of nanotechnology and photonics. His laboratory, located in HG 269, maintains active collaborations across multiple international institutions as evidenced by his extensive publication record. Dr. Fritzsche's research spans multiple nanotechnology domains with particular emphasis on plasmonic nanoparticles, nanozymes, and optical sensing platforms. His work demonstrates exceptional versatility across fundamental nanomaterial synthesis and practical biomedical applications. Recent projects include developing innovative antibiofilm agents using β-cyclodextrin inclusion complexes, engineering laccase-mimetic nanozymes for food safety monitoring, and creating plasmonic nanocomposites for antibacterial applications. His expertise in localized surface plasmon resonance (LSPR) sensing has led to significant advancements in real-time monitoring of nanomaterial interactions and biosensing platforms. Analysis of his recent publication trajectory reveals a strategic research focus on translating nanomaterial discoveries into practical diagnostic and therapeutic applications. His work demonstrates increasing integration of multiple nanotechnology approaches, particularly combining plasmonics with enzymatic mimetics and advanced imaging techniques. The consistent high-impact journal placements across chemistry, materials science, and biomedical engineering publications indicate strong cross-disciplinary recognition of his contributions to nanobiophotonics. While no specific awards are mentioned in the available documentation, Professor Fritzsche's leadership position at a Leibniz Association institute and his prolific publication record in top-tier journals represent significant professional recognition. His research program appears well-funded through the substantial output of collaborative papers spanning multiple application areas. Professor Fritzsche maintains an active research laboratory focused on nanobiophotonics, with particular expertise in plasmonic nanoparticle synthesis, surface functionalization techniques, and optical biosensing platforms. His team appears to specialize in bridging fundamental nanomaterial properties with practical biomedical applications, particularly in infection control, cancer therapy, and diagnostic technologies. The interdisciplinary nature of his publications suggests collaboration across chemistry, physics, biology, and medical research domains.

• Nanobiophotonics
• Plasmonic Nanoparticles
• Biosensors
• +۴ مورد دیگر

Cornelius Faber is a University Professor in the Department of Radiology at the University of Münster, Germany, where he leads the Experimental Nuclear Magnetic Resonance research group. His work focuses on developing and implementing novel MRI techniques that extend the boundaries of magnetic resonance imaging in terms of spatial and temporal resolution, sensitivity, and specificity for physiological, structural, and molecular changes. He actively participates in the "Cells in Motion" interdisciplinary research initiative at the university. Professor Faber's research spans multiple critical areas in medical imaging and biomedical science. His primary expertise lies in MRI cell tracking , enabling visualization of cellular dynamics in vivo. He has made significant contributions to infection imaging , developing methods to detect and characterize microbial infections using MRI. His work on MR methodology development has advanced quantitative imaging techniques, while his research on multimodal integration in MR and MRI contrast mechanisms has provided deeper insights into molecular and cellular processes. His research bridges physics, engineering, and biomedical applications, with particular relevance to inflammation, cancer, neurological disorders, and cardiovascular disease. Analysis of Professor Faber's extensive publication record reveals a clear evolution from fundamental MRI technique development toward increasingly sophisticated applications in disease models. His recent work demonstrates a strong trend toward multimodal imaging approaches that combine MRI with complementary techniques such as mass spectrometry, optical imaging, and PET. This integration creates comprehensive diagnostic platforms that provide both anatomical and molecular information. A notable pattern is the focus on cellular dynamics, particularly immune cell behavior in inflammatory conditions and tumor microenvironments, with applications spanning neuroscience, oncology, and cardiology. Professor Faber leads a multidisciplinary research team of approximately 15 members, including scientists, doctoral students, technicians, and medical students. His laboratory is deeply integrated with the University of Münster's research infrastructure, particularly the Multiscale Imaging Centre. The group's work contributes significantly to advancing preclinical MRI methodologies while maintaining strong clinical relevance, with numerous publications in high-impact journals across medical imaging, neuroscience, and biomedical engineering disciplines.

• MRI cell tracking
• infection imaging
• MR methodology
• +۶ مورد دیگر

Prof. Dr. Jochen Herms serves as Director at the LMU Center for Neuropathology and Prion Research , while maintaining a dual affiliation with the German Center for Neurodegenerative Diseases (DZNE) Munich as Head of Translational Brain Research. His work bridges clinical and experimental neuropathology, focusing on synaptic degeneration in neurodegenerative conditions. Ludwig-Maximilians-Universität München (LMU): Director, Experimental Neuropathology DZNE Munich: Translational Brain Research Research Themes: Primary: Biomedical Neuroscience Secondary: Cellular & Systems Neuroscience Tertiary: Behavioral & Cognitive Neuroscience Key investigations include: Physiological roles of neurodegenerative disease proteins (APP, presenilins, BACE, tau, α-synuclein) In vivo two-photon imaging of transgenic Alzheimer's models Neuronal calcium homeostasis in neurodegeneration High-throughput drug screening for AD/PD Active research collaborations leverage funding from: German Research Foundation (DFG) - Munich Cluster for Systems Neurology (EXC 2145 SyNergy) BMBF, BMWi, EU consortia Bavarian Research Foundation Wilhelm Sander Foundation

• Biomedical Neuroscience
• Cellular & Systems Neuroscience
• Behavioral & Cognitive Neuroscience
• +۵ مورد دیگر

Prof. Dr. med. Andreas Stahl is a faculty member at the University of Greifswald , serving as the Director of the University Eye Clinic . His work integrates clinical practice and research in ophthalmology, with a focus on retinal diseases. University: University of Greifswald Role: Director of the Clinic Contact: clinic-management-eyes@med.uni-greifswald.de Research Interests: Stahl’s research centers on retinopathy of prematurity (ROP) , anti-VEGF therapies , angiogenesis , and diabetic retinopathy . He explores pathophysiological mechanisms and innovative treatments for retinal vascular disorders, collaborating across disciplines to improve neonatal and adult ophthalmological outcomes. Recent Publications: His 2021–2022 work includes clinical decision support tools for ROP screening, comparative studies of ranibizumab and laser therapy, and analyses of retinal vascular occlusion post-COVID vaccination. These reflect his commitment to advancing treatment protocols and understanding disease mechanisms. Teaching: Involved in student education and e-learning development for ophthalmology. Projects: Participates in the INTERREG European Region Pomerania (INT118) initiative.

• Ophthalmology
• Retinopathy of Prematurity
• Angiogenesis
• +۳ مورد دیگر

Seraphine V. Wegner is a Full Professor at the Institute of Physiological Chemistry and Pathobiochemistry within the Medical Faculty of the University of Münster. She leads an active research group focused on the spatiotemporal control of cell-material and cell-cell interactions using visible light. Her work bridges synthetic biology, cell biology, and photochemistry to create innovative approaches for tissue engineering and minimal cellular systems. Dr. Wegner's educational background includes a PhD from the University of Chicago (2005-2010) and undergraduate studies at Middle East Technical University in Turkey (2002-2005). Her career path has taken her through prestigious institutions including the Max Planck Institutes in Mainz and Heidelberg, where she established her independent research before joining the University of Münster as a Full Professor in 2019. Her research spans several interconnected areas including light-controlled minimal cellular systems, photoswitchable cell-cell interactions for tissue engineering, light-controlled cell-material interactions, and engineering designer biofilms with light. These research themes share a common thread of using light as a non-invasive tool to precisely control biological processes with high spatial and temporal resolution. Dr. Wegner's publication record shows consistent high-impact output across leading journals in cell biology, synthetic biology, and materials science. Her recent work demonstrates increasing sophistication in multi-color light control systems and applications in both fundamental biological questions and potential therapeutic approaches. ERC Consolidator Grant (2024): LIGHTHOUSE - Light as a signal for nonchemical cell-to-cell communication ERC Starting Grant (2018): ARTIST - Artificial cell-cell interactions for light switchable cell organization and signaling Young Leaders in Science Program, Schering Foundation (2016) MaxSynBio Independent Group Leader, BMBF/MPG (2015) Her research group actively collaborates across disciplines, with projects spanning from fundamental biophysics of cell adhesion to potential medical applications in tissue engineering and bacterial therapeutics. Dr. Wegner has established herself as a leader in the emerging field of optogenetic control of multicellular systems.

• Synthetic Biology
• Cell Biology
• Photochemistry
• +۵ مورد دیگر

Dr. Thomas Spallek is a Junior Group Leader leading the Plant Biotic Interactions Group at Georg-August University Göttingen, Germany. His research focuses on functional genetics of parasitic plants, interspecific signaling, and haustoria formation mechanisms. Previously, he held roles as Project Leader (2019–2022) and Postdoc (2018–2019) at the University of Hohenheim, with postdoctoral experience at RIKEN (Japan) and The Sainsbury Laboratory (UK). Education: PhD in Plant Biology (Max Planck Institute, Cologne, 2011), Diploma in Biology (University of Konstanz, 2008). Research Interests: Parasitic plant genetics and host interactions Cytokinin signaling in plant-pathogen relationships Cellular and molecular mechanisms of haustorium development Publications span plant-parasite signaling, hormonal regulation, and genomic studies of parasitic weeds. Notable collaborations include work on Striga asiatica genome analysis and cytokinin-driven virulence factors. He is affiliated with the International Research Training Group 2172 - PRoTECT and coordinates the Plant Biotic Interactions research group. His work integrates molecular genetics, bioimaging, and computational tools to dissect plant defense and parasitic strategies.

• Plant Biology
• Parasitic Plant Genetics
• Plant-Microbe Interactions
• +۴ مورد دیگر